534 related articles for article (PubMed ID: 29713755)
1. Prognostic factors and prognostic models for renal cell carcinoma: a literature review.
Klatte T; Rossi SH; Stewart GD
World J Urol; 2018 Dec; 36(12):1943-1952. PubMed ID: 29713755
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in renal cell carcinoma.
Volpe A; Patard JJ
World J Urol; 2010 Jun; 28(3):319-27. PubMed ID: 20364259
[TBL] [Abstract][Full Text] [Related]
3. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
[TBL] [Abstract][Full Text] [Related]
4. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
5. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
Terakawa T; Miyake H; Kusuda Y; Fujisawa M
Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036
[TBL] [Abstract][Full Text] [Related]
6. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.
Klatte T; Gallagher KM; Afferi L; Volpe A; Kroeger N; Ribback S; McNeill A; Riddick ACP; Armitage JN; 'Aho TF; Eisen T; Fife K; Bex A; Pantuck AJ; Stewart GD
BMC Med; 2019 Oct; 17(1):182. PubMed ID: 31578141
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic factors in renal cell carcinoma].
Letang N; Cabaniols L; Pouessel D; Robert M; Iborra F; Culine S; Patard JJ; Guiter J; Thuret R
Bull Cancer; 2009 Apr; 96(4):475-84. PubMed ID: 19357021
[TBL] [Abstract][Full Text] [Related]
8. Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma.
Saeednejad Zanjani L; Madjd Z; Abolhasani M; Andersson Y; Rasti A; Shariftabrizi A; Asgari M
Exp Mol Pathol; 2017 Oct; 103(2):218-228. PubMed ID: 29050853
[TBL] [Abstract][Full Text] [Related]
9. Positive intratumoral chemokine (C-C motif) receptor 8 expression predicts high recurrence risk of post-operation clear-cell renal cell carcinoma patients.
Fu Q; Chang Y; Zhou L; An H; Zhu Y; Xu L; Zhang W; Xu J
Oncotarget; 2016 Feb; 7(7):8413-21. PubMed ID: 26716905
[TBL] [Abstract][Full Text] [Related]
10. Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC).
de Martino M; Klatte T; Seemann C; Waldert M; Haitel A; Schatzl G; Remzi M; Weibl P
BJU Int; 2013 Jun; 111(8):E348-53. PubMed ID: 23495750
[TBL] [Abstract][Full Text] [Related]
11. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice.
Bedke J; Heide J; Ribback S; Rausch S; de Martino M; Scharpf M; Haitel A; Zimmermann U; Pechoel M; Alkhayyat H; Shariat SF; Dombrowski F; Stenzl A; Burchardt M; Klatte T; Kroeger N
BJU Int; 2018 Jan; 121(1):84-92. PubMed ID: 28803448
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review.
Sun M; Shariat SF; Cheng C; Ficarra V; Murai M; Oudard S; Pantuck AJ; Zigeuner R; Karakiewicz PI
Eur Urol; 2011 Oct; 60(4):644-61. PubMed ID: 21741163
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
[TBL] [Abstract][Full Text] [Related]
14. Low NR3C2 levels correlate with aggressive features and poor prognosis in non-distant metastatic clear-cell renal cell carcinoma.
Zhao Z; Zhang M; Duan X; Deng T; Qiu H; Zeng G
J Cell Physiol; 2018 Oct; 233(10):6825-6838. PubMed ID: 29693713
[TBL] [Abstract][Full Text] [Related]
15. A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma.
Gremel G; Djureinovic D; Niinivirta M; Laird A; Ljungqvist O; Johannesson H; Bergman J; Edqvist PH; Navani S; Khan N; Patil T; Sivertsson Å; Uhlén M; Harrison DJ; Ullenhag GJ; Stewart GD; Pontén F
BMC Cancer; 2017 Jan; 17(1):9. PubMed ID: 28052770
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy for advanced renal cell carcinoma.
Meissner MA; McCormick BZ; Karam JA; Wood CG
Expert Rev Anticancer Ther; 2018 Jul; 18(7):663-671. PubMed ID: 29707987
[TBL] [Abstract][Full Text] [Related]
17. Medical treatment of renal cancer: new horizons.
Greef B; Eisen T
Br J Cancer; 2016 Aug; 115(5):505-16. PubMed ID: 27490806
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of extensive necrosis in renal cell carcinoma.
Collins J; Epstein JI
Hum Pathol; 2017 Aug; 66():108-114. PubMed ID: 28669641
[TBL] [Abstract][Full Text] [Related]
19. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
[TBL] [Abstract][Full Text] [Related]
20. Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinoma.
Wang C; Li Y; Chu CM; Zhang XM; Ma J; Huang H; Wang YN; Hong TY; Zhang J; Pan XW; Zheng JC; Jiang N; Hu CY; Ma X; Sun YH; Cui XG
EBioMedicine; 2019 Jan; 39():255-264. PubMed ID: 30558998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
